Chronic kidney disease (CKD) is also known as chronic kidney failure or renal disease is a condition characterized by a gradual loss of kidney function over time. Key market determinant include rising geriatric populace, increment in prevalence of CKD and favorable insurance policies in developed economies.
The report titled Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 provides detailed insights into key market determinants that impacted the market across geographies and drug types. The report also includes market estimation and forecast for CKD drugs for geographic region.
Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population. More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2021. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.
North America was the market leader interms of market revenues for CKD drugs market in 2021 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing in obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs. As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2022 to 2030. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 provides detailed insights into key market determinants that impacted the market across geographies and drug types. The report also includes market estimation and forecast for CKD drugs for geographic region.
Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population. More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2021. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.
North America was the market leader interms of market revenues for CKD drugs market in 2021 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing in obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs. As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2022 to 2030. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chronic Kidney Disease (CKD) Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Chronic Kidney Disease (CKD) Drugs market and their expected impact during the forecast period.
Market Segmentation
Drug Class
- Antihypertensive
- Antihyperlipidemic
- Anemia Treatment Drugs
- Swelling Treatment Drugs
- Other
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Chronic Kidney Disease (CKD) Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Chronic Kidney Disease (CKD) Drugs market?
- Which is the largest regional market for Chronic Kidney Disease (CKD) Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East Africa?
- Which are the key trends driving Chronic Kidney Disease (CKD) Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Chronic Kidney Disease (CKD) Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Chronic Kidney Disease (CKD) Drugs Market
2.2. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 (US$ Million)
2.3. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Chronic Kidney Disease (CKD) Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Vendors
3.2. Strategies Adopted by Chronic Kidney Disease (CKD) Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Chronic Kidney Disease (CKD) Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Chronic Kidney Disease (CKD) Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Antihypertensive
5.3.2. Antihyperlipidemic
5.3.3. Anemia Treatment Drugs
5.3.4. Swelling Treatment Drugs
5.3.5. Other
6. North America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
6.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7. UK and European Union Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
9. Latin America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
9.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
10. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
10.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
11. Company Profile
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Allergan plc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Amgen Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. AstraZeneca plc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. FibroGen
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. GlaxoSmithKline plc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Johnson & Johnson
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Keryx Biopharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Kissei Pharmaceutical Co., Ltd
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Sanofi S.A.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Teva Pharmaceutical Industries Ltd.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
List of Figures
Figure 1 Global Chronic Kidney Disease (CKD) Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Chronic Kidney Disease (CKD) Drugs Market: Quality Assurance
Figure 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021
Figure 6 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Chronic Kidney Disease (CKD) Drugs Market, 2021
Figure 8 Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Players, 2021
Figure 9 Global Chronic Kidney Disease (CKD) Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 Vs 2030, %
Figure 11 U.S. Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 2 North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 3 U.S. Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 4 Canada Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 5 Rest of North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 6 UK and European Union Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 7 UK Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 8 Germany Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 9 Spain Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 10 Italy Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 11 France Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 12 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 13 Asia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 14 China Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 15 Japan Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 16 India Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 17 Australia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 18 South Korea Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 19 Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 20 Brazil Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 21 Mexico Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 22 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 23 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 24 GCC Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 25 Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
Companies Mentioned
- AbbVie Inc.
- Allergan plc.
- Amgen Inc.
- AstraZeneca plc.
- F. Hoffmann-La Roche Ltd
- FibroGen
- GlaxoSmithKline plc.
- Johnson & Johnson
- Keryx Biopharmaceuticals Inc.
- Kissei Pharmaceutical Co.
- Ltd
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
